Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Yu, Min; Liu, Lei; Zhang, Binglan; Chen, Qi; Ma, Xuelei; Wu, Yuke; Liang, Chunshui; Niu, Zhimin; Qin, Xin; Niu, Ting

doi:10.7314/apjcp.2012.13.12.6077

Cited by 24 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their study on patients with a platelet count of less than 450,000/mm 3 , the 5-y survival rate was 70%, compared with 38% when the platelet count was 450,000/mm 3 or greater. The negative impact of thrombocytosis on prognosis has been also reported in other cancer types, such as bladder cancer (20), gynecologic malignancies (21)(22)(23), and gastrointestinal cancers (24), as well as in early and advanced breast cancer (25,26). According to different published studies, cytokines, in particular IL-6, play an important role in the development of thrombopoiesis and thrombocytosis (22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

et al. 2016

View full text Add to dashboard Cite

Radioligand therapy (RLT) with 177 Lu-PSMA-617 (PSMA is prostatespecific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on the therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT. Methods: RLT was performed in 40 hormone-refractory patients with distant metastases and progressive disease (mean age, 71.4 y). 68 Ga-PSMA-11 PET/CT was performed in all patients 1-2 wk before RLT. All patients were treated with a mean of 6 GBq. The SUV max of tumor lesions was determined using region-of-interest analysis. Complete blood counts, renal and liver function assessments, previous therapies, pain medication, and SUVs were included in the analysis. PSA was assessed 2 mo after RLT. Results: In the univariate analysis, younger age, higher levels of g-glutamyl transferase, lower pretherapeutic hemoglobin, a higher Gleason score, a higher number of platelets, higher C-reactive protein, regular need for pain medication, and higher lactate dehydrogenase had a negative impact on the therapeutic response; however, the multivariate analysis revealed that the most significant independent factors were the number of platelets and regular need for pain medication. The response was independent of the amount of PSMA uptake as well as previous therapies and other measured factors. Conclusion: A PSA decline of more than 50% was observed significantly more in patients without a regular need for analgesics.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In cancer patients, the hypercoagulable state is a hallmark of a more aggressive disease. Recently, several clinical studies have shown that hyperfibrinogenaemia and thrombocytosis are associated with human malignancies, such as lung cancer [14,15], endometrial cancer [16,17], ovarian cancer [18,19], and cervical cancer [11,12]. In our study, we demonstrated that elevated pretreatment fibrinogen and platelet levels correlated significantly with some risk factors, particularly recurrence, and that fibrinogen levels but not platelet levels acted as independent predictors of poor prognosis in patients with early-stage cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

“…However, to our knowledge, few studies have reviewed the prognostic value of pretreatment fibrinogen levels in early-stage cervical cancer. Regarding the relationship between cervical cancer and platelets, there is insufficient evidence available to evaluate the correlation between thrombocytosis and survival in patients with stage I-II cancer [12]. Furthermore, several studies involving locally advanced cancer stages have reported contradictory results [12].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Pretreatment Plasma Fibrinogen and Platelet Levels in Patients with Early-Stage Cervical Cancer

Zhao

Deng²,

Qin

et al. 2014

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Hyperfibrinogenaemia and thrombocytosis, which usually occur in cancer patients, have been shown to contribute to cancer cell growth, progression, and metastasis. The aims of the present study were to assess the prognostic significance of pretreatment plasma fibrinogen and platelet levels in early-stage cervical cancer patients. Methods: The present study was a retrospective analysis of 220 cervical cancer patients with stage I-IIA disease. The pretreatment plasma fibrinogen and platelet levels were investigated along with clinicopathological findings and survival data. Results: The incidences of hyperfibrinogenaemia and thrombocytosis were 11.8 and 25.5%, respectively. Elevated fibrinogen levels were associated with advanced tumour stage, older age, large tumour size, deep stromal invasion, and tumour recurrence, whereas higher platelet levels correlated significantly with advanced tumour stage, large tumour size, and tumour recurrence. Kaplan-Meier analysis showed that hyperfibrinogenaemia and thrombocytosis were significantly associated with shorter disease-free and overall survival. Furthermore, patients with hyperfibrinogenaemia and thrombocytosis may suffer from a higher risk of recurrence. Multivariate survival analyses showed that fibrinogen levels, but not platelet levels, were an independent prognostic factor for poor survival in early-stage patients. Conclusion: Hyperfibrinogenaemia and thrombocytosis may be valuable biomarkers for predicting recurrence in patients with early-stage cervical cancer.

show abstract

“…These findings were consistent with our previously meta-analysis on the link between thrombocytosis and survival in patients with gynecologic malignancies, which revealed that thrombocytosis associated with worse prognosis for patients with gynecologic malignancies but without specificity or sensitivity for the ones in advanced stage. [36] The publication year of the studies ranged from 2000-2012.…”

Section: Discussionmentioning

confidence: 99%

Thrombocytosis as a prognostic factor in patients with renal cell carcinoma: A meta-analysis of literature

Men¹,

Liang²,

Yu³

2015

J Can Res Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Cited by 24 publications

References 30 publications

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

Prognostic Significance of Pretreatment Plasma Fibrinogen and Platelet Levels in Patients with Early-Stage Cervical Cancer

Thrombocytosis as a prognostic factor in patients with renal cell carcinoma: A meta-analysis of literature

Contact Info

Product

Resources

About

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Cited by 24 publications

References 30 publications

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617

Prognostic Significance of Pretreatment Plasma Fibrinogen and Platelet Levels in Patients with Early-Stage Cervical Cancer

Thrombocytosis as a prognostic factor in patients with renal cell carcinoma: A meta-analysis of literature

Contact Info

Product

Resources

About

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617